SGLT-2 inhibitors canagliflozin, empagliflozin, and dapagliflozin showed overall comparable effectiveness on cardiovascular outcomes in T2D.

CardioOncology, shows that administration of the SGLT2 inhibitor empagliflozin to pigs receiving anthracyclines preserves ...

A groundbreaking study in Nature Cardiovascular Research uncovers promising drug targets for heart failure (HF) and its ...

A novel transcatheter-implanted system that shunts blood flow from the left to right atrium through the coronary sinus has ...

A new study finds SGLT2 inhibitors like Jardiance and GLP-1 drugs like Ozempic provide different benefits depending on the ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD exacerbation in adults with the disease and type 2 diabetes, researchers ...

Groundbreaking research reveals how common diabetes medications might offer unprecedented protection against heart attacks ...

Uncontrolled blood glucose (sugar) can lead to complications that may include cardiovascular disease ... “Both SGLT2 inhibitors and GLP-1 agonists are excellent drug categories that have improved the ...

A recent study from the FINEARTS-HF trial revealed that finerenone, which is an oral mineralocorticoid receptor antagonist, ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with ...